ReviewCurrent opinion in HIV and AIDS2025
Prospects for therapeutic T-cell vaccine strategies for HIV cure.
Review in Current opinion in HIV and AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characterisation of HIV-1 Gag Cytotoxic T-Lymphocyte Epitopes in the Southern African Region-A Systematic Review.Immunology · 2026Pooled it
- Learning from nature: HIV elite controllers as blueprints for a functional cure.Virology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review article aims to summaries the advances in T-cell vaccination as a component of HIV cure strategies. Recent clinical trials of therapeutic vaccination showing small but intriguing efficacy signals, provide the field with the data necessary to embark on informed combination strategies that build on these advances. The review focusses on aspects of T-cell immunogen design and vector use for vaccination, and discusses the effects of adjuvants and combination strategies on vaccine-induced immunity and their impact on virus control in people with HIV who undergo an analytical treatment interruption. RECENT
findingsVaccine-induced virus-specific T-cell immunity has been linked to relative control of viral replication in several recent clinical trials. Different immunogen concepts have also entered clinical trials, but for only a few are there immunogenicity and efficacy data available. New initiatives that leverage innate immune mechanisms show some interesting prospect to improve antiviral immunity. The available data also indicate that the preexisting T-cell immunity plays an important role in the strength and breadth of the vaccine-induced immunity. SUMMARY: With some efficacy data supporting the role of antiviral T-cell immunity, strategies that improve this response further can be delineated and incorporated into future, more potent combination approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.